#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i

In case there was any doubt: GCA leads to ischemic vision loss PMR does not #ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl

Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg

Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA ☝️Consider other dx if D2T PsA #ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ

Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m

After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R

#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T Zorpocabtagene-autoleucel/MB19.1: - 22/24 high degree efficacy - no relapse - no high grade CRS/ICANS *Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl

Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP

Phenotypes of GCA: Pt dx by PET compared to TA biopsy were: - younger -longer disease before dx -more frequent extremity claudication (still overall low) -less cranial / TA sx @RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db